By Anthony O. Goriainoff


Arecor Therapeutics PLC said Monday that its insulin candidate for diabetes, AT278, met all primary and secondary endpoints with positive headline results from the Phase 1 clinical trial.

The London-listed biopharmaceutical company--backed by Unilever PLC--said AT278 had the potential to significantly improve post prandial glucose control and reduce the injection volume and/or number of daily injections of people with diabetes who have a high daily insulin need.

"These positive data for AT278, the second product in our diabetes franchise, follow the earlier positive results from the Phase I clinical trial of AT247... Together they position Arecor with a unique combination of ultra-concentrated and ultra-rapid insulin candidates offering the potential to meet the broad needs of patients across the growing diabetes market," Chief Executive Sarah Howell said.


Write to Anthony O. Goriainoff at


(END) Dow Jones Newswires

September 20, 2021 03:16 ET (07:16 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Unilever (NYSE:UL)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Unilever Charts.
Unilever (NYSE:UL)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Unilever Charts.